Dr. Brufsky Discusses Pertuzumab in HER2+ Breast Cancer

Adam M. Brufsky, MD, PhD
Published: Monday, Nov 13, 2017



Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Brufsky says that the approval of pertuzumab would really only change dosing, as many clinicians are already using the drug to treat patients with HER2-positive breast cancer.
 
SELECTED
LANGUAGE


Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Brufsky says that the approval of pertuzumab would really only change dosing, as many clinicians are already using the drug to treat patients with HER2-positive breast cancer.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Publication Bottom Border
Border Publication
x